Compare GENB & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GENB | POET |
|---|---|---|
| Founded | 2018 | 1972 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Semiconductors |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2008 |
| Metric | GENB | POET |
|---|---|---|
| Price | $14.51 | $7.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $23.20 | N/A |
| AVG Volume (30 Days) | 294.5K | ★ 35.7M |
| Earning Date | 05-11-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $848.96 |
| Revenue Next Year | $16.58 | $700.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.00 | $3.87 |
| 52 Week High | $14.21 | $15.50 |
| Indicator | GENB | POET |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 47.28 |
| Support Level | $11.52 | $5.40 |
| Resistance Level | N/A | $9.14 |
| Average True Range (ATR) | 0.77 | 1.42 |
| MACD | 0.13 | -0.34 |
| Stochastic Oscillator | 81.65 | 8.11 |
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.